CDK inhibitors show wider cancer potential as combinations and biomarkers advance

MedicalXpress | mai 01, 2026

Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of cancer cells. Researchers see untapped potential in those targeted therapies, which can dramatically extend progression-free survival—the time before the disease grows worse—and overall survival, even in metastatic disease. Could those benefits be extended to patients with other types of cancer?